Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients: the SOLID study.

ABSTRACT:

Background

At present, we did not find any articles that studied seroprevalence and its persistence several months later in lung cancer patients in the setting of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection. Most patients with coronavirus disease 2019 (COVID-19) go on to develop antibodies (Abs) against viral proteins. However, it is not known how long these Abs last nor whether cancer treatments could affect the duration of immune response.

Methods

This prospective, longitudinal, multicenter serological study in the setting of SARS-CoV-2 infection was carried out in 50 Spanish hospitals. Eligibility criterion was the diagnosis of any lung cancer. The determination of anti-SARS-CoV-2 IgG Abs was performed by qualitative immuno-enzymatic assay using

SUBMITTER: Provencio M 

PROVIDER: S-EPMC8825652 | biostudies-literature | 2022 Jan

REPOSITORIES: biostudies-literature